Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial.
about
Measurable residual disease testing in acute myeloid leukaemia.Prognostic Significance of Mixed-Lineage Leukemia (MLL) Gene Detected by Real-Time Fluorescence Quantitative PCR Assay in Acute Myeloid Leukemia.The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia.Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders.Minimal Residual Disease in Acute Myeloid Leukemia.Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia.Enhancing acute myeloid leukemia therapy - monitoring response using residual disease testing as a guide to therapeutic decision-making.Fludarabine and cytarabine versus high-dose cytarabine in consolidation treatment of t(8; 21) acute myeloid leukemia: A prospective, randomized study.Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome.Redefining treatment failure for pediatric acute leukemia in the era of minimal residual disease testing.Minimal/measurable residual disease in AML: consensus document from ELN MRD Working Party.Methods of Detection of Measurable Residual Disease in AML.Distinct age-associated molecular profiles in acute myeloid leukemia defined by comprehensive clinical genomic profiling.
P2860
Q30234914-CD8C6731-57A8-43EA-85AD-A348742F6C26Q37234433-D2C5A084-A481-4181-AD8D-FA56EE604832Q37628021-BB7F436E-1D63-4A7C-8EB0-11A90A22CF43Q38904250-E67F7A20-FEC1-464E-969A-748CFD06EB7AQ39097771-F1B89113-F64C-4AF9-9A96-72EA90EFD411Q39132424-49625907-74EB-4422-9CB8-DCFFD1E62BF2Q39285841-3AC28F32-CC38-4ACA-B323-A46BE1806034Q40528087-57DD5A42-92D1-41F6-A3EF-640C42AF9882Q41138171-1501A7A9-4DB9-4F29-A7E4-08B8777F33EEQ46103668-4C11D8BF-8600-47EE-BE74-28994739F577Q47734674-97EC7B86-172A-4060-AC91-3365D96FBE1EQ47862030-8AB0AD7B-5213-4632-9717-A43E9911FF12Q55402884-7C00E08E-DEC2-4F14-903E-D51A58F7F300
P2860
Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Prospective long-term minimal ...... of the French CBF-2006 trial.
@en
type
label
Prospective long-term minimal ...... of the French CBF-2006 trial.
@en
prefLabel
Prospective long-term minimal ...... of the French CBF-2006 trial.
@en
P2093
P2860
P50
P1433
P1476
Prospective long-term minimal ...... of the French CBF-2006 trial.
@en
P2093
Aline Renneville
Cécile Pautas
Eric Jourdan
French AML Intergroup
Hervé Dombret
Nicolas Boissel
Odile Blanchet
Pascale Cornillet-Lefebvre
Romain Guieze
P2860
P304
P356
10.3324/HAEMATOL.2015.131946
P577
2015-12-03T00:00:00Z